Renal Denervation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented by Technology (Ultrasound Ablation, Radiofrequency Ablation, Pharmacologic Ablation, and Microinfusion), By Product (Catheters, Single Electrode Catheter, Multi Electrode Catheter, RF Generator, and Others), By Therapeutic Area (Hypertension, Heart Failure, Diabetes, Renal Failure, and Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, and Others), By Region and Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Global Renal Denervation Market is anticipated to witness a growth of steady CAGR in the forecast period, 2024-2028. It can be ascribed to increasing innovation of renal denervation system, increase in hypertension cases due to consuming alcohol, and unhealthy foods, growing usage of the endovascular catheter, radiofrequency ablation, and the continuous rise in the number of heart failure cases. However, increasing funding for R&D activities for treating renal abnormalities by various regulators and some state governments and the significant number of benefits of this method, along with the increasing efforts and initiatives being introduced by influential Market players, will propel the market in the forecast period. The occurrence of hypertension has increased from 17,307 per 100,000 in 1990 to 20,525 per 100,000 in 2015. The rising burden of chronic diseases like obesity among children and adults will power renal denervation market trends through the forecast period. The global renal denervation market is a rapidly growing industry that involves the use of advanced medical technologies to treat hypertension, or high blood pressure. Renal denervation is a minimally invasive procedure that uses radiofrequency ablation to disable the nerves that surround the kidneys. By doing so, the body's natural response to high blood pressure is reduced, leading to a decrease in blood pressure levels.

Rising incidence of hypertension among people

With the increasing modernization worldwide, people's lifestyles are majorly being changed. The day-to-day routines of people worldwide are increasingly becoming hectic. Hypertension is a significant and modifiable risk factor for cardiovascular disorders and diseases, chronic kidney disease, and death. The prevalence of hypertension has been observing a substantial rise over the past few years. Because more strict BP objectives are recommended by guidelines, obtaining these targets necessitates using multiple drugs, resulting in increased dosing complexity, expense, pill burden, and drug intolerance. Some significant reasons for an increase in the prevalence of hypertension are the increasing geriatric population, high sodium and low potassium intake, rising cases of obesity, increasing alcohol consumption in low- and middle-income countries, physical inactivity, and the lack of a balanced diet. The rising number of geriatrics worldwide is one of the primary reasons for an increase in the risk of hypertension. According to the World Health Organization, 2021, around 1.28 billion people aged between 30 and 79 are globally affected by hypertension. Renal denervation has been shown to be an effective treatment for hypertension, leading to an increase in demand for the procedure. As people age, the risk of developing hypertension increases. The world's population is aging rapidly, and this is contributing to the increasing prevalence of hypertension. The consumption of a diet high in salt, sugar, and saturated fats is a major risk factor for hypertension. The modern lifestyle has led to an increase in the consumption of processed and fast foods, which are often high in salt, sugar, and saturated fats. Lack of physical activity is another risk factor for hypertension. The modern lifestyle has led to a decrease in physical activity levels, leading to an increase in the prevalence of hypertension. Obesity is a major risk factor for hypertension. The prevalence of obesity is increasing across the globe, contributing to the increasing prevalence of hypertension. Hypertension can also be caused by genetic factors. Some people are more susceptible to hypertension due to their genetic makeup. Chronic stress can also contribute to the development of hypertension. Stress activates the sympathetic nervous system, leading to an increase in blood pressure. Smoking and alcohol consumption are also risk factors for hypertension. The prevalence of smoking and alcohol consumption is high in several countries, contributing to the increasing prevalence of hypertension. The increasing prevalence of hypertension across the globe is a result of several factors, including aging population, unhealthy diet, sedentary lifestyle, obesity, genetics, chronic stress, smoking, and alcohol consumption.

Rising demand for minimally invasive procedures

Minimally invasive procedures are becoming increasingly popular due to their many benefits, including faster recovery time, less pain, and reduced risk of complications. Renal denervation is a minimally invasive procedure that involves the use of a small catheter that is inserted through a small incision in the groin. This has led to an increase in demand for renal denervation procedures. Minimally invasive procedures are less invasive than traditional surgical procedures and involve smaller incisions. This leads to faster recovery times for patients, who can return to their normal activities more quickly. Minimally invasive procedures are associated with less pain than traditional surgical procedures, as they involve smaller incisions and less tissue damage. Minimally invasive procedures have a lower risk of complications than traditional surgical procedures, as they involve smaller incisions and less tissue damage. Minimally invasive procedures are often performed on an outpatient basis, which means that patients do not need to stay in the hospital for an extended period. This reduces the cost of the procedure and the burden on the healthcare system. Minimally invasive procedures have been shown to improve patient outcomes, including reduced pain, improved quality of life, and reduced risk of complications.

Advancement of Renal Denervation

The number of new capabilities introduced in the renal denervation approach is one of the major factors accelerating its adoption. Renal denervation systems that incorporate ultrasound technology can overcome the limitations of radiofrequency-based renal denervation systems. The high-frequency sound waves of the ultrasonic energy aid in ablating nerves without coming into close touch with the tissues. This aids in the prevention of renal artery damage. Due to this attribute, many patients worldwide prefer this technology. Moreover, integrating technology into these kinds of healthcare practices offer a considerable scale of enhancements in the outcomes of these techniques. The advancement of renal denervation will boost the market in the forecast period. Almost about 47% adults in the United States have hypertension, who have a systolic blood pressure greater than 130 mmHg or a diastolic blood pressure greater than 80 mmHg or are taking medication for hypertension. Only about 1 in 4 adults (24%) with hypertension have their condition under control. The development of advanced medical technologies has greatly improved the efficacy and safety of renal denervation procedures. For instance, radiofrequency ablation technology is now widely used in renal denervation procedures and has been shown to be highly effective in reducing blood pressure levels.

Increase in research and development Activities

Research and development activities in the field of renal denervation are increasing rapidly, leading to the development of new and innovative technologies for the treatment of hypertension. This is expected to further fuel market growth in the coming years. Governments in several countries are taking initiatives to promote healthcare, including the treatment of hypertension. For instance, in the United States, the Centers for Medicare and Medicaid Services (CMS) has approved reimbursement for renal denervation procedures, making it more accessible to patients. Several companies have developed next-generation renal denervation devices that use advanced technologies to deliver more precise and effective treatment. These devices use ultrasound, radiofrequency, or other forms of energy to ablate the nerves in the renal arteries, reducing blood pressure and improving patient outcomes. Recent studies have shown that the response to renal denervation varies among patients, and that some patients may not respond to the treatment at all. To address this, researchers are exploring the use of personalized treatment approaches, such as identifying biomarkers or using imaging techniques to guide the selection of patients who are most likely to benefit from the procedure.

Recent Development

  • EnligHTN Renal Denervation System: This system, developed by Boston Scientific, is a next-generation renal denervation device that uses radiofrequency energy to ablate the nerves in the renal arteries. It received CE mark approval in Europe in 2020 and is currently undergoing clinical trials in the United States.
  • Vessix Renal Denervation System: This system, developed by Mercator MedSystems, is a minimally invasive renal denervation device that uses pulsed ultrasound to ablate the nerves in the renal arteries. It received CE mark approval in Europe in 2020 and is currently undergoing clinical trials in the United States.


Download Free Sample Report

Market Segmentation

The Global Renal Denervation market is segmented based on technology, product, therapeutic area, end user, and by region. Based on technology, the market can be segmented into Ultrasound Ablation, Radiofrequency Ablation, Pharmacologic Ablation, and Microinfusion. Based on product, the market can be differentiated into Catheters, Single Electrode Catheter, Multi Electrode Catheter, RF Generator, and Others. Based on therapeutic area, the market can be differentiated into Hypertension, Heart Failure, Diabetes, Renal Failure, and Others. Based on end user, the market can be segmented into Hospitals & Clinics, Ambulatory Care Centers, and Others. Regionally, Europe dominated the market among Asia Pacific, North America, Middle East & Africa, and South America. In terms of country, the United States region dominates the global renal denervation market. According to CDC, in 2021, more than 670,000 deaths in the United States had hypertension as a primary or contributing cause.

Market Players

Medtronic Plc., Boston Scientific Corporation, Abbott Laboratories, Inc., Terumo Corporation, Johnson & Johnson, Cordis Corporation, ReCor Medical, Inc. (Otsuka Holdings), Cardiosonic Ltd, Mercator MedSystems, Inc, Renal Dynamics Limited are some of the leading players operating in the Global Renal Denervation Market.

Attribute

Details

Base Year

2022

Historic Data

2018 – 2021

Estimated Year

2023

Forecast Period

2024 – 2028

Quantitative Units

Revenue in USD Million, Volume in Units, and CAGR for 2018-2022 and 2022-2028

Report coverage

Revenue forecast, volume forecast, company share, competitive landscape, growth factors, and trends

Segments covered

By Technology

By Product

By Therapeutic Area

By End User

By Region

Regional scope

North America; Europe; Asia Pacific; South America; Middle East & Africa

Country scope

United States; Mexico; Canada; France; Germany; United Kingdom; Italy; Spain; China; India; South Korea; Japan; Australia; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE

Key companies profiled

Medtronic Plc., Boston Scientific Corporation, Abbott Laboratories, Inc., Terumo Corporation, Johnson & Johnson, Cordis Corporation, ReCor Medical, Inc. (Otsuka Holdings), Cardiosonic Ltd, Mercator MedSystems, Inc, Renal Dynamics Limited

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Report Scope:

In this report, Global Renal Denervation market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Renal Denervation Market, By Technology:
    • Ultrasound Ablation
    • Radiofrequency Ablation
    • Pharmacologic Ablation
    • Microinfusion
  • Renal Denervation Market, By Product:

o    Catheters

o    Single Electrode Catheter

o    Multi Electrode Catheter

o    RF Generator

o    Others

  • Renal Denervation Market, By Therapeutic Area:

o    Hypertension

o    Heart Failure

o    Diabetes

o    Renal Failure

o    Others

  • Renal Denervation Market, By End User:

o    Hospitals & Clinics

o    Ambulatory Care Centers

o    Others

  • Renal Denervation Market, By Region:
    • North America
      • United States
      • Mexico
      • Canada
    • Europe
      • France
      • Germany
      • United Kingdom
      • Italy
      • Spain
    • Asia Pacific
      • China
      • India
      • South Korea
      • Japan
      • Australia
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Egypt

§  Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Renal Denervation Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Renal Denervation Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Renal Denervation Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value

5.2.  Market Share & Forecast

5.2.1.     By Technology (Ultrasound Ablation, Radiofrequency Ablation, Pharmacologic Ablation, Microinfusion)

5.2.2.     By Product (Catheters, Single Electrode Catheter, Multi Electrode Catheter, RF Generator, Others)

5.2.3.     By Therapeutic Area (Hypertension, Heart Failure, Diabetes, Renal Failure, Others)

5.2.4.     By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)

5.2.5.     By Region

5.2.6.     By Company (2022)

5.3.  Market Map

5.3.1.     By Technology

5.3.2.     By Product

5.3.3.     By Therapeutic Area

5.3.4.     By End User

5.3.5.     By Region

6.    North America Renal Denervation Market Outlook

6.1.  Market Size & Forecast          

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Technology

6.2.2.     By Product

6.2.3.     By Therapeutic Area

6.2.4.     By End User

6.2.5.     By Country

6.3.  North America: Country Analysis

6.3.1.     United States Renal Denervation Market Outlook

6.3.1.1.         Market Size & Forecast

6.3.1.1.1.             By Value

6.3.1.2.         Market Share & Forecast

6.3.1.2.1.             By Technology

6.3.1.2.2.             By Product

6.3.1.2.3.             By Therapeutic Area

6.3.1.2.4.             By End User

6.3.2.     Mexico Renal Denervation Market Outlook

6.3.2.1.         Market Size & Forecast

6.3.2.1.1.             By Value

6.3.2.2.         Market Share & Forecast

6.3.2.2.1.             By Technology

6.3.2.2.2.             By Product

6.3.2.2.3.             By Therapeutic Area

6.3.2.2.4.             By End User

6.3.3.     Canada Renal Denervation Market Outlook

6.3.3.1.         Market Size & Forecast

6.3.3.1.1.             By Value

6.3.3.2.         Market Share & Forecast

6.3.3.2.1.             By Technology

6.3.3.2.2.             By Product

6.3.3.2.3.             By Therapeutic Area

6.3.3.2.4.             By End User

7.    Europe Renal Denervation Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Technology

7.2.2.     By Product

7.2.3.     By Therapeutic Area

7.2.4.     By End User

7.2.5.     By Country

7.3.  Europe: Country Analysis

7.3.1.     France Renal Denervation Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Technology

7.3.1.2.2.             By Product

7.3.1.2.3.             By Therapeutic Area

7.3.1.2.4.             By End User

7.3.2.     Germany Renal Denervation Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Technology

7.3.2.2.2.             By Product

7.3.2.2.3.             By Therapeutic Area

7.3.2.2.4.             By End User

7.3.3.     United Kingdom Renal Denervation Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Technology

7.3.3.2.2.             By Product

7.3.3.2.3.             By Therapeutic Area

7.3.3.2.4.             By End User

7.3.4.     Italy Renal Denervation Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Technology

7.3.4.2.2.             By Product

7.3.4.2.3.             By Therapeutic Area

7.3.4.2.4.             By End User

7.3.5.     Spain Renal Denervation Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Technology

7.3.5.2.2.             By Product

7.3.5.2.3.             By Therapeutic Area

7.3.5.2.4.             By End User

8.    Asia-Pacific Renal Denervation Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Technology

8.2.2.     By Product

8.2.3.     By Therapeutic Area

8.2.4.     By End User

8.2.5.     By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.     China Renal Denervation Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Technology

8.3.1.2.2.             By Product

8.3.1.2.3.             By Therapeutic Area

8.3.1.2.4.             By End User

8.3.2.     India Renal Denervation Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Technology

8.3.2.2.2.             By Product

8.3.2.2.3.             By Therapeutic Area

8.3.2.2.4.             By End User

8.3.3.     Japan Renal Denervation Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Technology

8.3.3.2.2.             By Product

8.3.3.2.3.             By Therapeutic Area

8.3.3.2.4.             By End User

8.3.4.     South Korea Renal Denervation Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Technology

8.3.4.2.2.             By Product

8.3.4.2.3.             By Therapeutic Area

8.3.4.2.4.             By End User

8.3.5.     Australia Renal Denervation Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Technology

8.3.5.2.2.             By Product

8.3.5.2.3.             By Therapeutic Area

8.3.5.2.4.             By End User

9.    South America Renal Denervation Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Technology

9.2.2.     By Product

9.2.3.     By Therapeutic Area

9.2.4.     By End User

9.2.5.     By Country

9.3.  South America: Country Analysis

9.3.1.     Brazil Renal Denervation Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Technology

9.3.1.2.2.             By Product

9.3.1.2.3.             By Therapeutic Area

9.3.1.2.4.             By End User

9.3.2.     Argentina Renal Denervation Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Technology

9.3.2.2.2.             By Product

9.3.2.2.3.             By Therapeutic Area

9.3.2.2.4.             By End User

9.3.3.     Colombia Renal Denervation Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Technology

9.3.3.2.2.             By Product

9.3.3.2.3.             By Therapeutic Area

9.3.3.2.4.             By End User

10.  Middle East and Africa Renal Denervation Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Technology

10.2.2.  By Product

10.2.3.  By Therapeutic Area

10.2.4.  By End User

10.2.5.  By Country

10.3.              MEA: Country Analysis

10.3.1.  South Africa Renal Denervation Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Technology

10.3.1.2.2.           By Product

10.3.1.2.3.           By Therapeutic Area

10.3.1.2.4.           By End User

10.3.2.  Saudi Arabia Renal Denervation Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Technology

10.3.2.2.2.           By Product

10.3.2.2.3.           By Therapeutic Area

10.3.2.2.4.           By End User

10.3.3.  UAE Renal Denervation Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Technology

10.3.3.2.2.           By Product

10.3.3.2.3.           By Therapeutic Area

10.3.3.2.4.           By End User

10.3.4.  Egypt Renal Denervation Market Outlook

10.3.4.1.      Market Size & Forecast

10.3.4.1.1.           By Value

10.3.4.2.      Market Share & Forecast

10.3.4.2.1.           By Technology

10.3.4.2.2.           By Product

10.3.4.2.3.           By Therapeutic Area

10.3.4.2.4.           By End User

10.3.5.  Turkey Renal Denervation Market Outlook

10.3.5.1.      Market Size & Forecast

10.3.5.1.1.           By Value

10.3.5.2.      Market Share & Forecast

10.3.5.2.1.           By Technology

10.3.5.2.2.           By Product

10.3.5.2.3.           By Therapeutic Area

10.3.5.2.4.           By End User

11.  Market Dynamics

11.1.              Drivers

11.2.              Challenges

12.  Market Trends & Developments

12.1.              Recent Developments

12.2.              Mergers & Acquisitions

12.3.              Product Launches

13.  Competitive Landscape

13.1.              Business Overview

13.2.              Company Snapshot

13.3.              Products & Services

13.4.              Financials (As reported)

13.5.              Recent Developments

13.6.              SWOT Analysis

13.6.1.  Medtronic Plc.

13.6.2.  Boston Scientific Corporation

13.6.3.  Abbott Laboratories, Inc.

13.6.4.  Terumo Corporation

13.6.5.  Johnson & Johnson

13.6.6.  Cordis Corporation

13.6.7.  ReCor Medical, Inc. (Otsuka Holdings)

13.6.8.  Cardiosonic Ltd

13.6.9.  Mercator MedSystems, Inc

13.6.10.                Renal Dynamics Limited

Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

Increasing hypertension along with demand for treatment of this disease and growing awareness about new technology the globe are the major drivers for the global renal denervation market.

down-arrow

Medtronic Plc., Boston Scientific Corporation, Abbott Laboratories, Inc., Terumo Corporation, Johnson & Johnson, Cordis Corporation, ReCor Medical, Inc. (Otsuka Holdings), Cardiosonic Ltd, Mercator MedSystems, Inc, Renal Dynamics Limited, are the leading players operating in the Global Renal Denervation Market.

down-arrow

Ultrasound Ablation is the segment type expected to dominate the Renal Denervation Market for the forecast period.

down-arrow

North America region is estimated to demonstrate significant growth during the forecast period.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Renal Denervation Market to be dominated by Ultrasound ablation type through 2028

Jan, 2023

Increasing cases of hypertension are expected to drive Global Renal Denervation Market in the forecast period 2024-2028.

Why Choose Us